UC4 High Impact Research and Research Infrastructure Cooperative Agreement Programs - Multi-Yr Funding
Limited Competition: Continuation of the Preventing Early Renal Loss in Diabetes (PERL) Study (UC4)
The purpose of this Funding Opportunity Announcement (FOA) is to complete treatment of the participants recruited into the Preventing Early Renal Loss in Diabetes (PERL) Study and to analyze the outcomes of the trial. PERL is a randomized, double-blind trial to test whether the medication, allopurinol, can slow the progression of kidney disease in people with type 1 diabetes and early diabetic kidney disease.
|Letter of Intent Due Date|
|Application Due Date|
March 2, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications
allowed for this funding opportunity announcement are due on this date.Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.